Celgene antibody could open door for new area of focus, says Wells Fargo Wells Fargo believes that Celgene is developing an anti-CD47 antibody that could enable the company to enter the immune-oncology space and pivot into biologics. The firm views the stock as undervalued, and believes that Celgene has many viable opportunities that could enable the stock to rise over the long-term. The firm keeps an Outperform rating on the shares and identifies it as a top pick.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.